Charting the path from pioneering
biology to impactful therapeutics.

We are a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer.

Learn More

Featured

“DNA Damage Response (DDR) Targets Beyond PARP” with Dr. Thomas Helleday

Distinguished scientist Thomas Helleday, PhD, examines emerging data and current mechanistic understandings of next generation clinical stage DDR targets in oncology, including Chk1. He will also review which drug targets are synergistic in combination with Chk1 inhibition, and discuss certain preclinical DDR targets currently generating interest in the field.

The DNA Damage Response (DDR) Network

DNA Damage Response (DDR) network is a system of cellular pathways that monitor, signal and repair DNA damage. In cancer cells, replication stress induced by oncogenes (e.g., MYC or RAS) or genetic mutations in DNA repair machinery (e.g., BRCA1 or FA) combined with loss of function in tumor suppressors (e.g., TP53 or ATM) results in persistent DNA damage and genomic instability. Targeted inhibition of the remaining components of the DDR network, such as by SRA737 or SRA141, may be synthetically lethal to cancer cells and have utility as a monotherapy in a range of tumor indications.